Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carbonyl iron-containing products side-effect data signify "need for caution," FDA says.

This article was originally published in The Tan Sheet

Executive Summary

CARBONYL IRON SIDE-EFFECT STUDIES SIGNIFY "NEED FOR CAUTION", FDA says, in evaluating "the limited evidence concerning the toxicity of carbonyl iron" in dietary supplements, the agency states in its denial of a Feb. 18 Rexall Sundown citizen petition concerning the Jan. 15 final rule on iron-containing drugs and supplements ("The Tan Sheet" Jan. 20, pp. 1-4). Rexall had sought both a reconsideration of the final rule and a stay of the warning label requirement for carbonyl iron-containing products ("The Tan Sheet" March 10, p. 9). Alternatively, Boca Raton, Fla.-based Rexall Sundown had requested a temporary exemption from the warning requirements.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel